HHS is exempting physicians from certain certification requirements needed to prescribe buprenorphine for opioid use disorder, the department announced Thursday (Jan. 14).
Forgot password?
Sign up today and your first download is free.
REGISTER
HHS is exempting physicians from certain certification requirements needed to prescribe buprenorphine for opioid use disorder, the department announced Thursday (Jan. 14).
The Pew Charitable Trusts unveiled a report earlier this month (Oct. 20) detailing ways states could expand access to naloxone, an opioid overdose-reversing drug, as state and local reports show overdoses are on the rise this year.
FDA’s risk mitigation programs for fentanyl and extended-release opioids are not suited to quickly address the opioid crisis, according to the HHS Office of Inspector General, which released a report Tuesday (Sept. 29) recommending the agency improve the programs.
A new Bipartisan Policy Center report on the opioid crisis says the federal government should do a better job using its opioid funds to target at-risk groups and should revisit Medicaid practices that restrict access to treatment.
Experts at the Commonwealth Fund who analyzed data for the group’s annual state scorecard say the results show the COVID-19 pandemic has exposed existing weaknesses in the health care system, including eroding coverage, persistent high costs and preventable deaths, that state and federal governments must partner to fix.
CMS on Thursday (July 30) released a request for information on whether the agency should grant Part D providers exceptions to electronic prescribing requirements for controlled substances and under what circumstances.
FDA will require drug makers to include naloxone co-prescribing information in labeling for all opioids and opioid use disorder medications, including buprenorphine, methadone and naltrexone, the agency announced Thursday (July 23).
HHS on Monday (July 13) finalized a rule that loosens privacy restrictions on substance use disorder records, inching towards fully aligning the strict privacy scheme with the less-stringent Health Insurance Portability and Accountability Act rules although additional rulemaking is needed for full alignment.
Four long overdue Medicaid guidance documents meant to help states tackle the nation’s opioid crisis are still missing, months after CMS and HHS officials promised the House Energy & Commerce health subcommittee in early March they’d get the guidance out sometime this spring.
The White House Office of Management and Budget on Tuesday (June 16) cleared a final Substance Use and Mental Health Services Administration rule that would loosen privacy restrictions on substance use records.
FDA and the National Telecommunications and Information Administration on Monday (June 8) launched a 120-day pilot program under which FDA will work with internet registries to flag and take action against any website that sells unapproved opioids online.
CMS plans to issue this spring several overdue Medicaid guidance documents meant to help states tackle the nation’s drug overdose crisis, an agency official told lawmakers Tuesday (March 3) in response to questions triggered by an Inside Health Policy investigation of the Trump administration’s lagging implementation of a major opioid law.
A federal committee tasked with coordinating government actions on substance use disorders met for the first time Friday (Feb. 28) and heard presentations from various government agencies on what they are doing to tackle the nation’s drug overdose crisis.
Behavioral health advocates sent a letter Friday (Feb. 14) to congressional leaders again calling for Congress to make a long-term investment in mental health clinics by extending the demo for two years and expanding the number of participating states as part of the May health care package.
In March, FDA’s newly established Controlled Substances Program will launch its Opioid Data Warehouse, which will allow the agency to integrate diverse data sources and enhance data analysis to pinpoint trends and new developments in the opioid crisis, FDA Deputy Center Director for Regulatory Programs Doug Throckmorton said Wednesday (Feb. 12).
The Trump administration’s proposed 2021 budget unveiled Monday (Feb. 10) would exempt qualified residential treatment programs from a restriction that prevents Medicaid from paying for inpatient stays in certain large facilities.
A leading telehealth company and health plans suggest closing the gap on access to mental and behavioral health services is a top priority for virtual care in 2020 as they continue to adjust telehealth services to consumers’ needs and push lawmakers to pass legislation expanding access to such services.
The 2021 Medicare Advantage and Part D proposed rule released Wednesday (Feb. 5) seeks to implement several new policies aimed at reducing opioid abuse in Medicare, including requiring Part D plans to establish drug management programs that would limit a beneficiary’s access to opioids if the beneficiary were deemed to be at risk of abuse.
The House Oversight & Reform Committee is already probing the Trump administration’s national drug strategy that was released Monday (Feb. 4), continuing the work of the late Chair Elijah Cummings (D-MD) who last year questioned the White House Office of National Drug Control Policy (ONDCP) on what he called an inadequate strategy.
The House Energy & Commerce health subcommittee on Wednesday (Jan. 29) discussed several legislative proposals that aim to reform drug manufacturing, update generic drug labels and increase FDA’s authorities over imported medical devices.
Manage various aspects of your NewsStand account from changing your password to editing your billing information.
© 2002-2021. Inside Washington Publishers